The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics

Research output: Contribution to journalArticlepeer-review

Abstract

Microalbuminuria is an early marker of diabetic nephropathy and its prevention is considered key for the primary prevention of diabetic nephropathy. Angiotensin-converting enzyme (ACE) inhibitors and nondihydropyridine calcium channel blockers (CCBs) have specific renoprotective properties in diabetes, and preliminary evidence is available that they are more effective in combination than either of the two agents alone in limiting albuminuria either in micro- or macroalbuminuric type 2 diabetic patients. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT) is a prospective, randomized, double-blind parallel-group study primarily aimed at evaluating the possibility of preventing the progression to microalbuminuria (urinary albumin excretion [UAE] rate 20-200 μg/min, i.e., incipient nephropathy) in 1209 hypertensive, type 2 diabetic patients with a normal UAE rate (

Original languageEnglish
Pages (from-to)442-461
Number of pages20
JournalControlled Clinical Trials
Volume24
Issue number4
DOIs
Publication statusPublished - Aug 2003

Keywords

  • ACE inhibitors
  • Calcium channel blockers
  • Diabetic nephropathy
  • Hypertension
  • Microalbuminuria
  • NIDD
  • Normoalbuminuria
  • Primary prevention

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): Design and baseline characteristics'. Together they form a unique fingerprint.

Cite this